Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer.

Saved in:
Bibliographic Details
Title: Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer.
Authors: Labrosse KB; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, Switzerland., Lombardo FC; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland., Bartoszek EM; Department of Biomedicine, Microscopy Core Facility, University of Basel, Basel, Switzerland., Sauteur L; Department of Biomedicine, Microscopy Core Facility, University of Basel, Basel, Switzerland., Tanner N; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland., Tanna T; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland., Wolf A; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland., Tunkova B; Sotio Biotech a.s., Prague, Czech Republic.; Department of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic., Kasikova L; Sotio Biotech a.s., Prague, Czech Republic., Fedier A; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland., Lopez MN; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland., Alborelli I; Institute of Biomedical Genetics and Pathology, University of Basel, Basel, Switzerland., Beisel C; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland., Kurzeder C; Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, Switzerland., Montavon C; Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, Switzerland., Fucíkova J; Sotio Biotech a.s., Prague, Czech Republic.; Department of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic., Heinzelmann-Schwarz V; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, Switzerland., Jacob F; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland. francis.jacob@unibas.ch., Coelho R; Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland. ricardojorge.bouca-novacoelho@unibas.ch.
Source: NPJ precision oncology [NPJ Precis Oncol] 2026 Feb 06; Vol. 10 (1). Date of Electronic Publication: 2026 Feb 06.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2397-768X
DOI:10.1038/s41698-026-01321-4